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ABSTRACT
The absolute insulin deficiency that occurs in type 1 
diabetes mellitus (T1DM) is associated with the need 
for intensive functional insulin therapy as the only 
appropriate treatment model. In the recent years, 
introduction of new classes of glucose-lowering drugs 
has led to an increasing interest in adjunct therapies 
for T1DM. These therapies are designed to support 
exogenous insulin therapy in achieving the therapeutic 
goal while reducing the risk of hypoglycaemia and ex-
erting a beneficial effect on body weight. One potential 
therapeutic option are sodium-glucose co-transporter 
2 (SGLT-2) inhibitors. In the present paper, we reviewed 
the current clinical research on SGLT-2 inhibitors as 
add-on therapy to insulin in patients with T1DM. This 
therapy modification contributes to an improvement in 
metabolic control without increasing the risk of severe 
hypoglycaemia and with a beneficial effect on body 
weight, translating to improved compliance, quality of 
life, and patient satisfaction with treatment. However, 
due to possible adverse effects including euglycaemic 
diabetic ketoacidosis, the decision to use SGLT-2 inhibi-
tors in patients with T1DM should be made with cau-
tion, and patients require proper education regarding 
the prevention and treatment of acidosis. (Clin Diabetol 
2020; 9; 3: 189–192)
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Introduction
Due to the pathophysiological mechanism of 
absolute insulin deficiency that mediates the de-
velopment of type 1 diabetes mellitus (T1DM), the 
affected patients require insulin substitution therapy 
along with its all inconveniences. Despite advances 
in insulin therapy over the last hundred years and 
introduction of glucose monitoring systems, many 
patients still do not attain optimal blood glucose and 
metabolic control and thus are at risk of more rapid 
development of chronic disease complications. In ad-
dition, even with adequate metabolic control, the risk 
of cardiovascular mortality in patients with T1DM is 
increased nearly 3-fold [1].
According to the Diabetes Poland guidelines, the 
recommended treatment model for T1DM is intensive 
functional insulin therapy using multiple subcutaneous 
insulin injections or continuous subcutaneous insulin 
infusion by a personal insulin pump [2]. However, 
this therapy continues to be associated with a risk of 
hypoglycaemia, which often makes the optimal blood 
glucose control more challenging, increases treat-
ment costs and reduces compliance, which ultimately 
reduces the quality of life. In addition, overweight or 
obesity and metabolic syndrome coexist in an increas-
ing number of patients with T1DM. In young patients 
with T1DM, insulin sensitivity is reduced compared to 
their healthy peers with similar body weight, physical 
activity level, and body fat content. Exogenous insulin 
therapy promotes further increase in body weight, 
which increases insulin requirement, thus creating 
a pathophysiological vicious circle, and may increase 
atherogenesis, accelerating the development of late 
diabetes complications including cardiovascular dis-
ease. All these factors result in an increasing interest in 
adjunct therapies to support exogenous insulin therapy 
in achieving the therapeutic goal while reducing the 
risk of hypoglycaemia and exerting a beneficial effect 
on body weight [3, 4]. 
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Effects of sodium-glucose co-transporter 2 
inhibitors in type 1 diabetes mellitus
One potential therapeutic option are sodium-
-glucose co-transporter 2 (SGLT-2) inhibitors. Inhibi-
tion of SGLT-2 leads to a number of beneficial effects 
including urinary caloric loss (leading to a reduced 
insulin requirement), body weight reduction, increased 
insulin sensitivity, blood pressure lowering, and reduced 
progression of albuminuria and diabetic nephropathy 
[5], all delaying the development of chronic complica-
tions of diabetes. SGLT-2 inhibitors are also effective in 
reducing the cardiovascular risk in patients with type 
2 diabetes mellitus. It was also shown that adding 
a SGLT-2 inhibitor reduces the risk of hypoglycaemia. 
Of note, SGLT-2 inhibitors act independently of insulin. 
Interestingly, SGLT-2 inhibitors are also believed to exert 
a protective effect on beta cell function, extending their 
insulin-secreting function [6].
Possible adverse effects of adjunct SGLT-2 inhibitor 
therapy in T1DM should be taken into account, of which 
clinically most important are urogenital infections and 
in particular euglycaemic diabetic ketoacidosis (EDKA). 
These effects may not only interfere with the therapeu-
tic process but also call for a careful patient selection 
for such therapy. EDKA is clearly a controversial issue. 
It is promoted by a reduced carbohydrate availability 
coupled with a reduced insulin dose. SGLT-2 inhibition 
increases glucosuria which leads to a reduced plasma 
insulin level, while the amount of exogenous insulin 
is reduced and at the same time glucagone level is in-
creased. A lower insulin to glucagone ratio stimulates 
ketogenesis and lipolysis (with circulating free fatty 
acid levels increased by 40% during a meal), which 
leads to increased lipid oxidation (on average by 20%) 
at the expense of carbohydrate oxidation [7]. Factors 
triggering EDKA include infections, reduced food and 
fluid intake, reduced insulin dose, and alcohol intake. 
Pathophysiologically, EDKA is similar to diabetic ketoaci-
dosis (DKA), except for glucosuria induced by SGLT-2 
inhibitors which ‘artificially’ lowers blood glucose level.
Overview of clinical studies using SGLT-2 
inhibitors in in type 1 diabetes mellitus
Currently, more and more reliable data indicate the 
efficacy of SGLT-2 inhibitors as adjunct therapy in T1DM.
The first SGLT-2 inhibitor approved for T1DM was 
dapagliflozin, the efficacy and safety of which was as-
sessed in the multicentre, randomized, double-blind, 
placebo-controlled DEPICT-1 and DEPICT-2 (Efficacy and 
Safety of Dapagliflozin in Patients with Inadequately 
Controlled Type 1 Diabetes) studies. The first of these 
studies was performed in Europe and North America, 
and the other included patients from North and Latin 
America, Europe, and Japan. The DEPICT studies as-
sessed the efficacy and safety of a 24-week dapagli-
flozin treatment in adult patients (18–75 years of age) 
with chronic inadequate diabetes control (haemoglobin 
A1c [HbA1c] levels 7.5–10.5%) who received dapagliflo-
zin 5 mg (n = 259), dapagliflozin 10 mg (n = 259), 
or placebo (n = 260) daily. In the study protocol, the 
patients were advised to reduce the daily insulin dose by 
not more than 20% after taking the first dapagliflozin 
dose. The DEPICT-1 trial showed a significant reduction 
of HbA1c level (primary endpoint) by 0.42% in the 5 mg 
group and 0.45% in the 10 mg group (P < 0.0001 for 
both doses). A reduction was also noted in the daily in-
sulin dose (by 8.8% and 13.2%, respectively; P < 0.0001 
for both doses) and body weight (by 2.96% and 3.72%, 
respectively; P < 0.0001 for both doses). The propor-
tion of patients with HbA1c level reduction by ≥ 0.5% 
without severe hypoglycaemia was significantly higher 
in both dapagliflozin groups compared to placebo. In 
addition, in the patient subgroup that used continuous 
glucose monitoring (CGM), addition of dapagliflozin 
was shown to result in a significant improvement of 
the mean daily glucose levels, with an increase of the 
time in blood glucose level target range by 9.1% in 
the 5 mg group and 10.1% in the 10 mg group (P < 
< 0.0001 for both doses). Severe hypoglycaemia oc-
curred in 8%, 6%, and 7% of patients, respectively, 
in the 5 mg, 10 mg, and placebo groups. Urogenital 
infections were noted more frequently in the active 
treatment groups, while the rates of other adverse 
effects were similar in all study groups. The incidence 
of DKA was also similar in all study groups. EDKA was 
reported in only 2 patients in the 10 mg dapagliflo-
zin group. The positive effects of adjunct dapagliflo-
zin therapy were maintained at the end of extended 
follow-up period (overall 52 weeks), with a significant 
reduction in HbA1c level and body weight. During this 
period, overall 9 cases of EDKA were reported, includ-
ing one in the placebo group [8]. The DEPICT-2 trial 
was performed in a study population of a similar size 
and showed consistent results regarding the efficacy 
of dapagliflozin in the treatment of T1DM. CGM data 
showed a similar reduction in blood glucose levels in the 
active treatment groups, and similar reductions were 
noted in HbA1c levels, body weight, and daily insulin 
dose [9]. In March 2019, based on the DEPICT-1 and 
DEPICT-2 study results, the European Medicines Agency 
(EMA) approved dapagliflozin at the dose of 5 mg daily 
as an adjunct therapy in patients with T1DM and body 
mass index (BMI) ≥ 27 kg/m2 in whom insulin therapy 
only is not sufficient for optimal metabolic control [10], 
but this therapy was not approved by the U.S. Food 
and Drug Administration (FDA).
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Another somewhat unusual drug of this class is 
sotagliflozin. It has not been approved for the treat-
ment of type 2 diabetes mellitus and is active against 
both SGLT-2 and SGLT-1. Sotagliflozin has been ap-
proved by EMA was for the treatment of T1DM based 
on the results of the inTandem studies [11] but again, 
no approval was granted by FDA. The inTandem study 
program included 3 multicentre, randomized, double-
blind, placebo-controlled trials. The inTandem-2 and 
inTandem-1 studies evaluated sotagliflozin 200 mg and 
400 mg compared to placebo. The primary endpoint 
was HbA1c level change at 24 weeks of therapy. The 
first of these studies was conducted in Europe and 
the other one in North America. Both included similar 
numbers of patients (sotagliflozin 400 mg: n = 263 
in the inTandem-2 study, n = 262 in the inTandem-1 
study; sotagliflozin 200 mg: n = 261 and n = 263, re-
spectively; placebo: n = 258 and n = 268, respectively). 
In both studies, the protocol called for the greatest re-
duction in postprandial insulin dosing (by 30%), which 
was likely related to the additional incretin effect of 
this drug. Both trials showed significant reductions in 
HbA1c level (P < 0.001 for both doses), body weight 
(by 2–3.5 kg, P < 0.001 for both doses), and daily in-
sulin dose (by 6.2–9.7%, P < 0.001 for both doses). In 
the inTandem-2 study, the proportion of patients with 
achieved HbA1c level < 7% was 27.2%, 27.8%, and 
15.5%, respectively, in the sotagliflozin 200 mg, sotag-
liflozin 400 mg, and placebo groups. In the inTandem-1 
study, these proportions were 30%, 35.5%, and 20.9%, 
respectively. In patients using CGM systems, adjunct 
therapy with sotagliflozin was shown to increase the 
time in blood glucose level target range by 5.4% and 
11.7%, respectively, for the 200 mg and 400 mg doses 
(P = 0.026 for the 200 mg dose; P < 0.001 for the 400 
mg dose). These positive effects on HbA1c levels, body 
weight, and daily insulin requirement were maintained 
at 52 weeks of follow-up in both sotagliflozin groups, 
and the reported satisfaction with treatment increased 
significantly. The rates of severe hypoglycaemia were 
lower, while diarrhoea and fungal genital infections 
were more common in the sotagliflozin groups. The 
rate of DKA at 52 weeks in the inTandem-2 study was 
2.3%, 3.4%, and 0%, respectively, in the sotagliflozin 
200 mg, sotagliflozin 400 mg, and placebo groups. 
In the inTandem1 study, these rates were 3.4%, 4.2%, 
and 0.4%, respectively. Of 36 cases of DKA reported in 
these two studies combined, 13 cases occurred with 
blood glucose levels < 250 mg/dL. The inTandem3 study 
showed that addition of sotagliflozin 400 mg contrib-
uted to an improved metabolic control, with a signifi-
cantly higher proportion of patients with HbA1c level 
< 7.0% at 24 weeks of follow-up (28.6% vs. 15.2%, 
P < 0.001). In addition, the active treatment was as-
sociated with positive effects regarding the reduction 
of HbA1c level (−0.46%), body weight (−2.98 kg), 
systolic blood pressure (−3.5 mm Hg), and daily insulin 
dose (−2.8 units daily) (P ≤ 0.002 for all comparisons). 
The rate of severe hypoglycaemia was similar in both 
groups (3.0% vs. 2.4% in the placebo group). The rate 
of ketoacidosis was higher in the sotagliflozin group 
(3.0% vs. 0.6% in the placebo group), while the rates of 
other adverse effects were similar in both groups [12].
Long-term safety and efficacy in the treatment of 
T1DM has also been documented for empagliflozin. 
The EASE-2 and EASE-3 (Empagliflozin as Adjunctive 
to inSulin thErapy) studies evaluated the effect of 
add-on empagliflozin therapy on HbA1c levels in adult 
patients with chronic inadequate T1DM control (HbA1c 
level 7.5–10%). The EASE-2 trial studied empagliflozin 
10 mg (n = 243) and 25 mg (n = 244) vs. placebo 
(n = 243), and the EASE-3 trial studied empagliflozin 
2.5 mg (n = 241), 10 mg (n = 248) and 25 mg (n = 245) 
vs. placebo (n = 241). 
Study participants were advised to reduce the daily 
insulin dose by 10% at the trial initiation. At 26 weeks, 
a significant reduction of HbA1c level was noted for all 
empagliflozin doses compared to placebo (P < 0.0001). 
Both trials showed a reduction of body weight and 
blood glucose level variation, and an increase in the 
CGM time in range. Systolic blood pressure and daily 
insulin requirement were also reduced. In addition, the 
EASE-2 study showed that the positive effects of em-
pagliflozin were maintained during a longer follow-up 
of 52 weeks. Severe hypoglycaemia occurred in 1.2%, 
4.1%, 2.7%, and 3.1% of patients receiving empagli-
flozin 2.5 mg, 10 mg, 25 mg, or placebo, respectively. 
The rate of genital infections was insignificantly higher 
in the active treatment groups. DKA was reported in 
0.8%, 4.3%, 3.3%, and 1.2% of patients in the empa-
gliflozin 2.5 mg, 10 mg, 25 mg, and placebo groups, 
respectively. These studies indicated that the 2.5 mg 
dose was both effective at improving metabolic con-
trol in T1DM and safe, as it was not associated with 
an increased risk of severe hypoglyceamia and EDKA 
[13]. Of note, this dose is not sufficiently effective in 
the treatment of type 2 diabetes mellitus.
Similar results of phase 3 clinical trials are currently not 
available for canagliflozin and ertugliflozin. Smaller phase 2 
clinical trials with canagliflozin showed that both 100 mg 
and 300 mg doses were effective in reducing HbA1c level, 
body weight, and daily insulin requirement [14].
Summary
In view of the studies reviewed above, SGLT-2 
inhibitors seem an effective and relatively safe thera-
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peutic option as an adjunct therapy in T1DM. Most 
benefits from such therapy may be expected in patients 
with chronically uncontrolled diabetes, abnormal 
body weight (overweight or obesity), and those us-
ing relatively large insulin doses. As noted above, the 
risk of ketoacidosis including EDKA is a limitation that 
necessitates careful patient selection for adjunct SGLT-
2 inhibitor therapy in T1DM. Poor candidates for such 
therapy include patients with risky behaviours including 
excessive alcohol intake, use of psychoactive substances/ 
/illicit drugs, and use of a low-calorie low-carbohydrate 
diet. Inadequate access to a physician is also a contrain-
dication for adding a SGLT-2 inhibitor in patients with 
T1DM. According to the American Diabetes Association 
expert consensus published in February 2019, patients 
with HbA1c levels > 10% are also not candidates for 
SGLT-2 inhibitor therapy due to a high rate of ketoaci-
dosis in this group (> 15% during a 5-year follow-up) 
even without SGLT-2 inhibitor therapy [15].
The patients must be educated not to reduce the 
insulin dose by more than 10–20% when initiating 
SGLT-2 inhibitor therapy. The smallest effective dose 
of any drug of this class should be used. In addition, 
the drug should be immediately withdrawn in acute 
conditions associated with a possible DKA trigger such 
as fasting, infection or other acute illness. The drug 
should also be withdrawn 72 hours before elective 
surgery. Patients treated with SGLT-2 inhibitors require 
monitoring of not only blood glucose levels but also 
the presence of ketone bodies in serum and urine. 
Of note, EDKA is not associated with the warning of 
symptomatic hyperglycaemia, and thus patients should 
be alert to such symptoms as nausea, vomiting, lack 
of appetite, fatigue, and dyspnoea, occurring even 
with blood glucose levels < 250 mg/dL. The manage-
ment of EDKA associated with SGLT-2 inhibitor use is 
summarized by the STICH mnemonic (STopping SGLT-2 
inhibitor therapy, Injecting insulin, consuming Carbo-
hydrates, Hydrating, monitoring ketones) [16].
In summary, adding a SGLT-2 inhibitor as an ad-
junct to insulin therapy in T1DM has been shown to 
be an effective therapeutic approach. Such therapy 
modification contributes to a better disease control as 
evidenced by lower HbA1c levels and body weight and 
improved CGM parameters without an increased risk of 
severe hypoglycaemia. It also seems that these benefits 
translate to improved compliance, quality of life, and 
patient satisfaction with treatment. However, not all 
patients with T1DM are candidates for such therapy 
due to possible adverse effects including the most dan-
gerous complication of (euglycaemic) DKA. Patients in 
whom SGLT-2 inhibitor therapy is considered must be 
well educated, with an emphasis on the identification 
of DKA symptoms and triggers, and the management 
of this condition should it occur.
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